The Pediatrician's Role in Preventing Cervical Cancer

Abstract

Get full access to this article

View all access options for this article.

References

World Health Organization. Initiative for Vaccine Research (IVR) human papillomavirus. http://www.who.int/vaccine_research/diseases/viral_cancers. Accessed November 27, 2006.

Ferlay J. , Bray F. , Pisani P. , Parkin DM Globocan 2002: cancer incidence, mortality and prevalence worldwide. http://www.-dep.iarc.fr. Accessed November 27, 2006 .

Parkin D. , Bray F. , Ferlay J. , Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.

Jemal A. , Siegel R. , Ward E. , et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.

Centers for Disease Control. Human papillomavirus . In: Atkinson WHJ , McIntyre L , Wolfe S , eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 10th ed. Washington DC: Public Health Foundation; 2007.

Walboomers JM , Jacobs MV , Manos MM , et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.

CDC Advisory Committee on Immunization Practices. Press Release: CDCs advisory committee recommends human papillomavirus vaccination . http://www.cdc.gov/od/oc/media/pressrel/r060629.htm . Updated July 3, 2006. Accessed November 29, 2006 .

Ziv A. , Boulet JR , Slap GB Utilization of physician offices by adolescents in the United States. Pediatrics. 1999;104:35-42.

Munoz NB , Castellsague FX , de Sanjose M. , et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278-285.

10.

Ries L. , Melbert D. , Krapcho M. , et al (eds). SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute, http:seer.cancer.gov/csr .1975_2004/, based on November 2006 SEER data submission, posted to the SEER Web site 2007.

11.

Clifford GM , Smith JS , Plummer M. , Munoz N. , Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88:63-73.

12.

Liaw KL , Glass AG , Manos MM , et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst. 1999;91:954-960.

13.

Schlecht NF , Kulaga S. , Robitaille J. , et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA . 2001;286:3106-3114. 14. Moscicki AB , Schiffman M. , Kjaer S. , Villa LL Chapter 5: updating the natural history of HPV and anogenital cancer . Vaccine. 2006;24(suppl 3):42S-51S.

14.

Wheeler CM , Hunt WC , Schiffman M. , Castle PE Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis. 2006;194: 1291-1299.

15.

Brown DR , Shew ML , Qadadri B. , et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005;191:182-192.

16.

Moscicki AB , Hills N. , Shiboski S. , et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001;285:2995-3002.

17.

Boardman LA , Stanko C. , Weitzen S. , Sung CJ Atypical squamous cells of undetermined significance: human papillomavirus testing in adolescents. Obstet Gynecol . 2005;105:741-746.

18.

National Cancer Institute. Recent studies regarding HPV and cervical cancer: questions and answers. http://www.cancer.gov/cancertopics/factsheet/HPVCervicalQandA . Updated July 27, 2005. Accessed November 29, 2006.

19.

Dunne EF , Unger ER , Sternberg M. , et al. Prevalence of HPV infection among females in the United States . JAMA. 2007;297:813-819.

20.

Ho GY , Bierman R. , Beardsley L. , Chang CJ , Burk RD Natural history of cervicovaginal papillomavirus infection in young women . N Engl J Med. 1998;338: 423-428.

21.

Carter JJ , Koutsky LA , Hughes JP , et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181:1911-1919.

22.

Agorastos TM , Lambropoulos D. , Chrisafi AF , et al. Detection and typing of human papillomavirus DNA in uterine cervices with coexistent grade I and grade III intraepithelial neoplasia: biologic progression or independent lesions? Eur J Obstet Gynecol Reprod Biol. 2005;121:99-103.

23.

Park J. , Sun D. , Genest DR , et al. Coexistence of low and high grade squamous intraepithelial lesions of the cervix: morphologic progression or multiple papillomaviruses? Gynecol Oncol. 1998;70:386-391.

24.

Ostor AG Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12:186-192.

25.

Clifford GM , Smith JS , Aguado T. , Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003;89:101-105.

26.

National Cancer Institute. Cervical cancer: screening. http://www.cancer.gov/cancertopics/pdq/screening/cervical/healthprofessional. Updated July 21, 2006. Accessed January 17, 2007.

27.

Nanda K. , McCrory DC , Myers ER , et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132:810-819.

28.

Irwin K. , Montano D. , Kasprzyk D. , et al. Cervical cancer screening, abnormal cytology management, and counseling practices in the United States. Obstet Gynecol . 2006;108:397-409.

29.

Ronco G. , Cuzick J. , Pierotti P. , et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening randomised controlled trial. BMJ. 2007;335(7609):28.

30.

Feldman S. How often should we screen for cervical cancer? N Engl J Med . 2003;349:1495-1496.

31.

National Cancer Institute. Cancer trends progress report 2005-Update. http://www.progressreport.cancer.gov/doc. Accessed January 16, 2007.

32.

American Cancer Society. Cancer Facts & Figures. 2002.

33.

National Cancer Institute. The Pap test: questions and answers. http://www.cancer.gov/cancertopics/factsheet/Detection/Pap-test. Accessed August 18, 2007.

34.

Chesson HW , Blandford JM , Gift TL , Tao G. , Irwin KL The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health. 2004 ;36:11-19.

35.

Markowitz LE , Dunne EF , Saraiya M. , et al. Quadrivalent Human Papillomavirus Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2007;56:1-24.

36.

Centers for Disease Control and Prevention. Sexually Transmitted Diseases. HPV Vaccine Questions and Answers. http://www.cdc.gov/std/hpv/STDFact-HPV-vaccine.htm. Accessed August 7, 2007.

37.

Insinga RP , Dasbach EJ , Myers ER The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis. 2003;36:1397-1403.

38.

Ireland JA , Reid M. , Powell R. , Petrie KJ The role of illness perceptions: psychological distress and treatment-seeking delay in patients with genital warts. Int J STD AIDS. 2005;16:667-670.

39.

Goldie SJ , Kohli M. , Grima D. , et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604-615.

40.

Gardasil® Human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant. Whitehouse Station, NJ 08889: Merck & Co. Inc; 2007.

41.

CERVARIX® Product Information Human Papillomavirus Vaccine Types 16 and 18 (Recombinant, AS04 adjuvanted). Rixensart, Belgium: GlaxoSmithKline Australia Pty Ltd; 2007.

42.

Jansen KU , Rosolowsky M. , Schultz LD , et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation . Vaccine. 1995;13:1509-1514.

43.

Kirnbauer R. , Chandrachud LM , O' Neil BW , et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology . 1996;219:37-44.

44.

Suzich JA , Ghim SJ , Palmer-Hill FJ , et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A. 1995;92:11553-11557.

45.

Vogel FR Improving vaccine performance with adjuvants. Clin Infect Dis. 2000;30(suppl 3):266S-270S.

46.

Lehtinen M. , Apter D. , Dubin G. , et al. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS. 2006;17:517-521.

47.

Lehtinen M. , Idanpaan-Heikkila I. , Lunnas T. , et al. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy. Int J STD AIDS. 2006;17:237-246.

48.

Villa LL , Costa RL , Petta CA , et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271-278.

49.

Villa LL , Costa RL , Petta CA , et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459-1466.

50.

The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-1927.

51.

Ault KA Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369:1861-1868.

52.

Garland SM , Hernandez-Avila M. , Wheeler CM , et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356: 1928-1943.

53.

Harper DM , Franco EL , Wheeler C. , et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757-1765.

54.

Harper DM , Franco EL , Wheeler CM , et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247-1255.

55.

Paavonen J. , Jenkins D. , Bosch FX , et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007. In press.

56.

Reisinger KS , Block SL , Lazcano-Ponce E. , et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007;26:201-209.

57.

Block SL , Nolan T. , Sattler C. , et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118:2135-2145.

58.

Gall S. , Teixeira J. , Wheeler C. , et al. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV 16/18 ASO4 candidate vaccine . American Association of Cancer Research Annual Meeting; April 2007; Los Angeles, CA.

59.

Weng NP Aging of the immune system: how much can the adaptive immune system adapt ? Immunity. 2006; 24:495-499.

60.

Myers ER , McCrory DC , Nanda K. , Bastian L. , Matchar DB Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151:1158-1171.

61.

Profile of Pediatric Visits. Annualized Estimates 2000-2004. AAP Analysis of 2000-2004 National Ambulatory Medical Care Survey. Elk Grove Village, IL: American Academy of Pediatrics; 2007.

62.

Kahn JA , Zimet GD , Bernstein DI , et al. Pediatricians' intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health. 2005;37:502-510.

63.

Moscicki AB Impact of HPV infection in adolescent populations . J Adolesc Health. 2005;37:3S-9S.

64.

Brown D. HPV type 6/11/16/18 vaccine: first analysis of cross-protection against persistent infection, cervical intraepithelial neoplasia (CIN), and adenocarcinoma in situ (AIS) caused by oncogenic HPV types in addition to 16/18. Paper presented at: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2007; Chicago, IL.